Breast Cancer highlights of the ESMO 2023 Congress

Professor Hope Rugo shares her insights on the breast cancer highlights of #ESMO23 meeting, and also how they apply them in clinical practice. This was a really interesting meeting for breast cancer, we heard a lot of updates about antibody drug conjugates , immunotherapy and endocrine therapy. - DESTINY-Breast04 trial: trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer - BEGONIA Phase Ib/II trial: Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer - TROPION-Breast01 trial:  a phase III trial that investigated datopotamab deruxtecan. - KEYNOTE-522:  showed statistically significant and clinically meaningful improvements in pCR and EFS with the addition of pembrolizumab to chemotherapy in patients with early-stage TNBC. - CHECKMATE-7FL: investigating neoadjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy followed by adjuvant nivolumab or placebo plus endocrine therapy. Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-highlights-esmo-2023-congress